Medical Condition News

RSS

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Study: More attention needs to be paid for cartilage during RA diagnosis

This could lead to a paradigm shift in the treatment of rheumatoid arthritis: rheumatologists at the Medical University of Vienna have discovered, through a secondary study involving 3,000 female patients, that the condition of the cartilage in inflammatory joint rheumatism needs to be paid more attention than has previously been the case. Until now, the focus lay mainly on investigating the damage to the bone.

23 Aug 2011

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.

23 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Phadia launches new allergy and autoimmunity testing instruments

Today Phadia, the global leader in allergy and autoimmune related diseases diagnostics, announced the launch of Phadia's new allergy and autoimmunity testing instruments; Phadia 2500 and Phadia 5000.

23 Aug 2011

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

CTI responds to EMA's Day 120 letter for pixantrone MAA

Cell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Aug 2011

Stem cells of oral mucosa stay young, says Tel Aviv University researcher

While highly potent embryonic stem cells are often the subject of ethical and safety controversy, adult-derived stem cells have other problems. As we age, our stem cells are less pliant and less able to transform into the stem cells that science needs to find breakthrough treatments for disease.

23 Aug 2011

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Under an $11-million grant from the National Institutes of Health (NIH), Dartmouth Medical School (DMS) will lead a network of northern New England institutions in recruiting, training, and supporting young quantitative biologists to teach and conduct research into the ways that genes and the environment work together to trigger and prevent disease.

23 Aug 2011

Almost all heart attack patients receive angioplasty within 90 minutes of being admitted

Almost all heart attack patients who need the emergency artery-opening procedure known as angioplasty are receiving it within 90 minutes of being admitted to the hospital, a marked improvement from five years ago when most patients waited longer for the life-saving procedure, according to a report by Yale School of Medicine researchers and their colleagues.

23 Aug 2011

New research reveals stubbornly low public awareness of bowel cancer

BRITONS have very low awareness of the signs and symptoms of bowel cancer - the third most common cancer in the UK and second largest cause of cancer deaths each year, new research shows.

23 Aug 2011

ARUP Laboratories introduces Affymetrix CytoScan HD Array

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, is pleased to introduce its newest SNP-based microarray technology, the Affymetrix CytoScan HD Array.

23 Aug 2011

AstraZeneca announces availability of BRILINTA tablets in the U.S. pharmacies

AstraZeneca today announced that BRILINTA tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.

23 Aug 2011

Vertex receives Health Canada approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated today announced that Health Canada has approved INCIVEK tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

23 Aug 2011

MME, WNDM sign major agreement to distribute CellerateRX

Wound Management Technologies, Inc., a leader in advanced wound care solutions, today announced a major distribution deal with Marketing Media Enterprises, LLC (MME), an Orlando Florida medical products distributor serving the direct-to-consumer and military market.

23 Aug 2011

Nurse safety measures around highly toxic drugs needed

Nearly 17 percent of nurses who work in outpatient chemotherapy infusion centers reported being exposed on their skin or eyes to the toxic drugs they deliver, according to a new study from the University of Michigan Comprehensive Cancer Center.

22 Aug 2011